Dubai Telegraph - 'Remarkable' Alzheimer's drug reduces cognitive decline, study shows

EUR -
AED 3.879454
AFN 71.766172
ALL 98.446538
AMD 408.727287
ANG 1.903424
AOA 962.189651
ARS 1055.136057
AUD 1.630409
AWG 1.901181
AZN 1.789518
BAM 1.961728
BBD 2.132343
BDT 126.201335
BGN 1.9588
BHD 0.398064
BIF 3118.741826
BMD 1.056211
BND 1.421281
BOB 7.297188
BRL 6.105428
BSD 1.056091
BTN 89.136639
BWP 14.496666
BYN 3.456143
BYR 20701.745225
BZD 2.128773
CAD 1.480962
CDF 3026.046048
CHF 0.937129
CLF 0.037557
CLP 1036.439301
CNY 7.636301
CNH 7.645963
COP 4727.78219
CRC 539.429963
CUC 1.056211
CUP 27.989605
CVE 110.599191
CZK 25.276513
DJF 188.054673
DKK 7.458575
DOP 63.873001
DZD 141.196108
EGP 52.131744
ERN 15.843172
ETB 130.910644
FJD 2.402194
FKP 0.833686
GBP 0.831777
GEL 2.883565
GGP 0.833686
GHS 16.976135
GIP 0.833686
GMD 74.991397
GNF 9102.504493
GTQ 8.155953
GYD 220.943428
HKD 8.217753
HNL 26.666577
HRK 7.53423
HTG 138.767993
HUF 406.15981
IDR 16809.289017
ILS 3.948874
IMP 0.833686
INR 89.180057
IQD 1383.48038
IRR 44458.579959
ISK 146.095547
JEP 0.833686
JMD 167.185173
JOD 0.748958
JPY 164.521312
KES 136.515348
KGS 91.231852
KHR 4289.881246
KMF 492.563931
KPW 950.589942
KRW 1479.650439
KWD 0.32489
KYD 0.880043
KZT 523.582077
LAK 23200.543009
LBP 94573.658376
LKR 308.542304
LRD 194.845062
LSL 19.330811
LTL 3.118718
LVL 0.638891
LYD 5.158587
MAD 10.547972
MDL 19.130443
MGA 4948.044906
MKD 61.515768
MMK 3430.533723
MNT 3589.00659
MOP 8.466021
MRU 41.984863
MUR 49.842827
MVR 16.318166
MWK 1831.198548
MXN 21.74186
MYR 4.732353
MZN 67.489547
NAD 19.330811
NGN 1774.287045
NIO 38.86892
NOK 11.740652
NPR 142.624361
NZD 1.797365
OMR 0.406676
PAB 1.056111
PEN 4.024312
PGK 4.184644
PHP 62.056118
PKR 293.325825
PLN 4.325535
PYG 8247.922253
QAR 3.849933
RON 4.976236
RSD 117.044056
RUB 105.092045
RWF 1449.953783
SAR 3.967208
SBD 8.854807
SCR 14.362927
SDG 635.317643
SEK 11.596225
SGD 1.417832
SHP 0.833686
SLE 24.097471
SLL 22148.231865
SOS 603.523631
SRD 37.343937
STD 21861.445383
SVC 9.240923
SYP 2653.762908
SZL 19.339168
THB 36.814269
TJS 11.257603
TMT 3.707302
TND 3.335479
TOP 2.473748
TRY 36.27907
TTD 7.170667
TWD 34.391332
TZS 2809.522312
UAH 43.536853
UGX 3875.711004
USD 1.056211
UYU 44.865568
UZS 13525.870313
VES 47.523829
VND 26827.771874
VUV 125.395551
WST 2.94851
XAF 657.932577
XAG 0.034763
XAU 0.000412
XCD 2.854464
XDR 0.795596
XOF 657.976316
XPF 119.331742
YER 263.843317
ZAR 19.268254
ZMK 9507.174232
ZMW 28.963064
ZWL 340.099669
  • RBGPF

    -0.9400

    59.25

    -1.59%

  • CMSC

    0.0250

    24.635

    +0.1%

  • BCC

    -1.9800

    140.57

    -1.41%

  • BCE

    -0.1350

    27.075

    -0.5%

  • NGG

    0.4850

    62.605

    +0.77%

  • RIO

    -0.1710

    60.449

    -0.28%

  • RELX

    0.0550

    46.175

    +0.12%

  • GSK

    -0.0550

    35.055

    -0.16%

  • BTI

    0.2750

    35.695

    +0.77%

  • JRI

    -0.0100

    13.23

    -0.08%

  • RYCEF

    -0.2900

    6.82

    -4.25%

  • SCS

    -0.1500

    13.22

    -1.13%

  • CMSD

    0.0350

    24.765

    +0.14%

  • VOD

    -0.0200

    8.73

    -0.23%

  • BP

    0.3800

    28.95

    +1.31%

  • AZN

    0.4450

    65.735

    +0.68%

'Remarkable' Alzheimer's drug reduces cognitive decline, study shows
'Remarkable' Alzheimer's drug reduces cognitive decline, study shows / Photo: Philippe LOPEZ - AFP/File

'Remarkable' Alzheimer's drug reduces cognitive decline, study shows

US pharmaceutical giant Eli Lilly on Wednesday announced its experimental Alzheimer's drug significantly slowed cognitive and functional decline, results hailed as "remarkable" by experts despite some patients experiencing serious side effects.

Text size:

In an analysis of nearly 1,200 people in the early stages of the disease, donanemab slowed the progression of symptoms by 35 percent over a period of 18 months compared to placebo.

This was measured by cognition and their ability to carry out daily tasks like managing finances, driving, engaging in hobbies and conversing about current events in a standardized index called the Integrated Alzheimer's Disease Rating Scale (iADRS).

Side effects included temporary swelling in parts of the brain, which occurred in almost a quarter of the treated patients, as well as microhemorrhages that occurred in 31 percent of patients on the treatment arm and 14 percent of patients in the placebo group.

Two participants' deaths were attributed to the side effects, while a third might have also died from the treatment.

Nonetheless, the data was widely praised by independent experts, who said donanemab had the potential, if approved, to significantly improve the lives of people suffering from the most common form of dementia.

The news comes after the US approved another Alzheimer's drug in January, Biogen and Eisai's lecanemab, which slowed the rate of cognitive decline by 27 percent and was also declared a blockbuster by experts.

Biogen and Eisai had also developed aducanumab, known by the trade Aduhelm, which was given US approval in 2021, though that decision was mired in controversy and led to a damning report by Congress.

In addition to severe side effects, Aduhlem's clinical effectiveness was ambiguous, which is so far not the case for the two subsequent drugs.

Lilly said it would rapidly submit its results to the US Food and Drug Administration (FDA) as well as other global regulators.

"We are extremely pleased that donanemab yielded positive clinical results with compelling statistical significance for people with Alzheimer's disease in this trial," said Daniel Skovronsky, Lilly's chief scientific and medical officer, in a statement.

Mark Mintun, a top Lilly executive in neuroscience R&D, added however that "like many effective treatments for debilitating and fatal diseases, there are associated risks that may be serious and life-threatening."

Eli Lilly's stock price rose 4.3 percent after Wednesday's announcement.

- Targeting amyloid -

In Alzheimer's disease, two key proteins, tau and amyloid beta, build up into tangles and plaques, known together as aggregates, which cause brain cells to die and lead to brain shrinkage.

Like lecanemab (also known by its trade name Leqembi), donanemab is an antibody therapy that targets amyloid beta.

Experts said that the results for both drugs validated the theory that removing amyloid beta does improve the course of the disease, and that future therapies targeting both proteins might have even better outcomes.

Nick Fox, of the UK Dementia Research Institute, said that although the full dataset was not yet available, the results announced by press release "confirms that we are in a new era of disease modification for Alzheimer's disease."

"This clinical trial is a real breakthrough, demonstrating a remarkable 35% slowing of cognitive decline in Alzheimer's patients with high amyloid beta but low tau burden," added Marc Busche, UK Dementia Research Institute group leader at University College London.

"These are the strongest phase 3 data for an Alzheimer's treatment to date," said Maria Carrillo, chief science officer at the US Alzheimer's Association. "This further underscores the inflection point we are at for the Alzheimer's field."

Alzheimer's disease accounts for 60-80 percent of dementia, according to the Alzheimer's Association. It progressively destroys thinking and memory, eventually robbing people of the ability to carry out the simplest of tasks.

G.Gopinath--DT